BMRN
Biomarin Pharmaceutical Inc
57.20$
-2.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -675.0% | -244.2% | -132.8% | -197.2% | -385.0% | -618.2% | -349.5% | -244.2% | -59.5% | -28.4% | -3.1% | 27.0% | 5.0% | 4.2% | 3.5% | -10.9% | -9.8% | -24.9% | -20.4% | -0.7% | 1.4% | 2.8% | 4.6% | 16.5% | 8.4% | 6.6% | 20.1% | 25.7% | |
| 66.7% | 123.7% | 75.5% | 59.9% | 61.1% | 78.0% | 71.2% | 39.2% | 14.2% | 0.9% | 5.9% | 6.5% | 7.4% | 8.2% | 9.0% | 8.6% | 7.6% | 5.3% | 8.7% | 6.7% | 6.4% | 6.2% | 5.7% | 5.9% | 4.9% | 4.3% | 3.4% | 2.5% | |
| – | – | – | – | – | – | – | – | – | – | 9.6% | 11.1% | 10.2% | 9.9% | 9.5% | 12.1% | 11.8% | 12.5% | 12.1% | 10.7% | 10.0% | 9.4% | 10.2% | 10.7% | 9.4% | 8.6% | 7.1% | 5.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | -48.9% | 13.4% | 7.7% | 15.8% | 3.6% | -15.9% | 41.7% | 6.0% | 1.3% | 3.3% | -36.1% | 10.0% | 1.4% | – | – | – | |
| 66.7% | 30.2% | 7.3% | -23.1% | -14.1% | -52.1% | 22.9% | 29.2% | -35.1% | -10.9% | -30.0% | 6.1% | -11.2% | -5.7% | 6.6% | -4.2% | -4.0% | 5.2% | -14.4% | -7.2% | -3.3% | -5.9% | -12.1% | 3.6% | -4.6% | -13.9% | -7.6% | -3.4% | |
| 533.3% | 432.9% | 38.7% | 152.3% | 34.9% | 49.4% | 129.2% | 11.5% | 29.2% | 18.4% | 19.0% | 27.7% | 13.1% | 34.9% | 8.9% | 11.9% | 15.9% | 25.6% | 13.3% | 15.2% | 9.7% | 8.5% | 7.4% | 6.5% | 5.8% | 4.4% | 3.4% | 3.2% | |
| -683.3% | -1,297.2% | -16.0% | -1,144.7% | 509.4% | -421.1% | -82.0% | 224.4% | -231.3% | -124.2% | -6.4% | -24.5% | -26.9% | -20.3% | -39.1% | -54.5% | 26.0% | -132.6% | -43.3% | -23.3% | 17.7% | -1.8% | -2.9% | -19.8% | -1.0% | -4.6% | 4.8% | -12.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 0.6% | 3.9% | 0.2% | 0.7% | – | – | – | |
| – | – | – | – | – | 71.2% | – | – | – | – | – | – | 8.8% | 7.6% | -0.3% | -1.2% | -1.0% | -2.6% | -5.3% | -2.6% | -2.4% | -2.5% | -2.7% | -2.5% | -2.6% | -3.2% | -2.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -3.8% | -0.7% | -0.1% | 129.9% | -0.1% | 0.0% | 43.1% | 36.7% | -25.1% | -0.3% | 11.3% | -0.2% | -0.1% | 0.0% | -17.3% | 0.0% | |
| 1,641.7% | 1,805.5% | 77.9% | 1,307.7% | 27.7% | 1,764.2% | -149.6% | 117.2% | 351.4% | 267.0% | 7.7% | -19.6% | 0.9% | 6.6% | 62.4% | 136.1% | 24.8% | 104.3% | 65.1% | 38.6% | -26.0% | -4.4% | 9.7% | 0.0% | -0.9% | -0.8% | -18.4% | -1.3% | |
| 283.3% | 264.2% | -70.9% | -34.2% | 151.7% | 725.4% | -581.1% | 97.4% | 60.6% | 114.5% | -1.8% | -17.2% | -21.0% | -9.5% | 26.8% | 70.8% | 40.9% | -53.8% | 1.0% | 14.4% | -7.0% | -3.3% | 11.4% | -3.4% | 6.5% | 1.3% | 6.6% | 11.5% | |
| -1,208.3% | -677.1% | -171.5% | -349.4% | -420.0% | -667.5% | -478.6% | -255.7% | -88.7% | -46.8% | -22.1% | -0.6% | -8.2% | -30.7% | -5.4% | -22.7% | -25.7% | -50.5% | -33.7% | -15.8% | -8.3% | -5.7% | -2.8% | 10.0% | 2.6% | 2.1% | 16.7% | 22.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.